Trial
NCT00861471
Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Novartis
Condition
Prostate Cancer
Intervention
Docetaxel
Why stopped
due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-30